search
Back to results

Glutamatergic Modulation as a Treatment for Depressive Symptoms Among Patients With Post-acute Sequelae of COVID (PASC): A Pilot Trial

Primary Purpose

Post-acute Sequelae of COVID-19, Depressive Symptoms, Cognitive Dysfunction

Status
Recruiting
Phase
Phase 2
Locations
United States
Study Type
Interventional
Intervention
CI-581a
CI-581b
Sponsored by
New York State Psychiatric Institute
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Post-acute Sequelae of COVID-19 focused on measuring Ketamine, PASC, Long Covid

Eligibility Criteria

18 Years - 65 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: Meeting the case-definition for PASC with depressive symptoms Otherwise physically healthy No adverse reactions to study medications Capacity to consent and comply with study procedures, including sufficient proficiency in English Sexually active participants must use an effective form of birth control (condom plus spermicide, diaphragm plus spermicide, or birth control pills) before and throughout their study participation. Willingness to provide one or more emergency contacts to the study team Exclusion Criteria: Meeting the DSM-5 criteria for lifetime history of bipolar disorder, schizophrenia, or any psychotic illness. Lifetime history of delirium, dementia, amnesia, or dissociative disorders Current suicide risk or a history of suicide attempt within the past year Pregnant or interested in becoming pregnant during the study period. Any of the following cardiac conditions: clinically significant left ventricular hypertrophy, angina, clinically significant arrhythmia within 1 year of signing study consent form. Unstable physical disorders which might make participation hazardous such as hypertension (>160/90), anemia, active hepatitis or other liver disease (transaminase levels <3 X the upper limit of normal will be considered acceptable), epilepsy, or untreated diabetes. Participants reporting HIV+ status will be asked to provide information about their current treatment, including all medications. Participants who are on the antiretroviral ritonavir (Norvir) will be excluded due to the possibility that ketamine in combination with this medication may increase the risk of drug-induced hepatitis. Previous history of a substance use disorder with the study medications, and/or a history of an adverse reaction/experience with prior exposure to the study medications. Recent history of significant violence (past 2 years) leading to an individual incurring physical harm, police involvement, or resulting in legal action. On psychotropic or other medications whose effect could be disrupted by participation in the study. Other personal circumstances and behavior judged to be incompatible with establishment of rapport or safe exposure to the study medications. Physiologic dependence on a substance including benzodiazepines, alcohol, or opioids.

Sites / Locations

  • New York State Psychiatric InstituteRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Experimental

Arm Label

CI-581a+CI-581b

CI-581b+CI-581a

Arm Description

Administration of CI-581a at 0.8mg/kg during week 1. Administration of CI-581b at 0.025mg/kg during week 3.

Administration of CI-581b at 0.025mg/kg during week 1. Administration of CI-581a at 0.8mg/kg during week 3.

Outcomes

Primary Outcome Measures

Reduction in depressive symptoms

Secondary Outcome Measures

Improvement in neurocognitive symptoms of PASC

Full Information

First Posted
December 30, 2022
Last Updated
March 30, 2023
Sponsor
New York State Psychiatric Institute
search

1. Study Identification

Unique Protocol Identification Number
NCT05690503
Brief Title
Glutamatergic Modulation as a Treatment for Depressive Symptoms Among Patients With Post-acute Sequelae of COVID (PASC): A Pilot Trial
Official Title
Glutamatergic Modulation as a Treatment for Depressive Symptoms Among Patients With Post-acute Sequelae of COVID (PASC): A Pilot Trial
Study Type
Interventional

2. Study Status

Record Verification Date
March 2023
Overall Recruitment Status
Recruiting
Study Start Date
March 20, 2023 (Actual)
Primary Completion Date
December 31, 2023 (Anticipated)
Study Completion Date
December 31, 2023 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
New York State Psychiatric Institute

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
Post-acute sequelae of SARS-CoV2 (PASC), colloquially known as "long-COVID," is thought to affect between 10-30% of all COVID-19 survivors. Patients with PASC also report worsening behavioral health symptoms over time that include new-onset depression, anxiety, and even suicidal behavior. The purpose of this randomized, double-blind, controlled trial is to test the efficacy of a glutamate modulator among PASC patients suffering from new-onset or worsening of depressive symptoms.
Detailed Description
While PASC symptoms have been identified in nearly every organ system, the most common symptoms include fatigue, cognitive and attention deficits (known as 'brain fog'), shortness of breath, and post-exertional malaise. New-onset depression, anxiety, and even suicidal behavior have also been reported. Symptoms of PASC can exhibit daily variation; additionally PASC frequently demonstrates a relapsing and remitting course. This is mitigated by cognitive and emotional stress, physical exertion, diet, and alcohol consumption; therefore, measuring treatment response and the course of illness over time can be challenging. While there are many ongoing trials evaluating a variety of treatments for PASC, no clear treatment has emerged; additionally, there are no published data on psychotropic medications alleviating the inflammatory response and psychiatric symptoms in PASC. Alterations in the transmission between neurons of a neurotransmitter called glutamate are an important target of pharmacotherapy for PASC. Glutamate modulators have demonstrated promise in improving depressive symptoms and suicidality and can improve cognitive functioning among patients with these symptoms. The study team has recently developed a novel design that integrates a clinical trial involving serial infusions. The current trial will evaluate the effect of a sub-anesthetic infusion on individuals with PASC and depressive symptoms who complete a randomized, double-blind, placebo-controlled pilot study conducted over 5 weeks using a cross-over and counterbalanced design.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Post-acute Sequelae of COVID-19, Depressive Symptoms, Cognitive Dysfunction
Keywords
Ketamine, PASC, Long Covid

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Crossover Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
12 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
CI-581a+CI-581b
Arm Type
Experimental
Arm Description
Administration of CI-581a at 0.8mg/kg during week 1. Administration of CI-581b at 0.025mg/kg during week 3.
Arm Title
CI-581b+CI-581a
Arm Type
Experimental
Arm Description
Administration of CI-581b at 0.025mg/kg during week 1. Administration of CI-581a at 0.8mg/kg during week 3.
Intervention Type
Drug
Intervention Name(s)
CI-581a
Intervention Description
Medication infusion intravenously over 90 minutes.
Intervention Type
Drug
Intervention Name(s)
CI-581b
Intervention Description
Medication infusion intravenously over 90 minutes.
Primary Outcome Measure Information:
Title
Reduction in depressive symptoms
Time Frame
from baseline to week 5.
Secondary Outcome Measure Information:
Title
Improvement in neurocognitive symptoms of PASC
Time Frame
from baseline to week 5.

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Meeting the case-definition for PASC with depressive symptoms Otherwise physically healthy No adverse reactions to study medications Capacity to consent and comply with study procedures, including sufficient proficiency in English Sexually active participants must use an effective form of birth control (condom plus spermicide, diaphragm plus spermicide, or birth control pills) before and throughout their study participation. Willingness to provide one or more emergency contacts to the study team Exclusion Criteria: Meeting the DSM-5 criteria for lifetime history of bipolar disorder, schizophrenia, or any psychotic illness. Lifetime history of delirium, dementia, amnesia, or dissociative disorders Current suicide risk or a history of suicide attempt within the past year Pregnant or interested in becoming pregnant during the study period. Any of the following cardiac conditions: clinically significant left ventricular hypertrophy, angina, clinically significant arrhythmia within 1 year of signing study consent form. Unstable physical disorders which might make participation hazardous such as hypertension (>160/90), anemia, active hepatitis or other liver disease (transaminase levels <3 X the upper limit of normal will be considered acceptable), epilepsy, or untreated diabetes. Participants reporting HIV+ status will be asked to provide information about their current treatment, including all medications. Participants who are on the antiretroviral ritonavir (Norvir) will be excluded due to the possibility that ketamine in combination with this medication may increase the risk of drug-induced hepatitis. Previous history of a substance use disorder with the study medications, and/or a history of an adverse reaction/experience with prior exposure to the study medications. Recent history of significant violence (past 2 years) leading to an individual incurring physical harm, police involvement, or resulting in legal action. On psychotropic or other medications whose effect could be disrupted by participation in the study. Other personal circumstances and behavior judged to be incompatible with establishment of rapport or safe exposure to the study medications. Physiologic dependence on a substance including benzodiazepines, alcohol, or opioids.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Saleena Subaiya, MD
Phone
646-774-6117
Email
saleena.subaiya@nyspi.columbia.edu
First Name & Middle Initial & Last Name or Official Title & Degree
Kate O'Malley, MA
Phone
646-774-6117
Email
kate.omalley@nyspi.columbia.edu
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Saleena Subaiya, MD
Organizational Affiliation
New York State Psychiatric Institute
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Elias Dakwar, MD
Organizational Affiliation
New York State Psychiatric Institute
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Kate O'Malley, MA
Organizational Affiliation
New York State Psychiatric Institute
Official's Role
Study Director
Facility Information:
Facility Name
New York State Psychiatric Institute
City
New York
State/Province
New York
ZIP/Postal Code
10032
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Saleena Subiaya, MD
Email
saleena.subaiya@nyspi.columbia.edu
First Name & Middle Initial & Last Name & Degree
Kate O'Malley, MA
Email
kate.omalley@nyspi.columbia.edu

12. IPD Sharing Statement

Learn more about this trial

Glutamatergic Modulation as a Treatment for Depressive Symptoms Among Patients With Post-acute Sequelae of COVID (PASC): A Pilot Trial

We'll reach out to this number within 24 hrs